Advertisement
MNOV vs VIR
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is MNOV is a Hold and VIR is a StrongBuy.
MNOV's Stochastic Oscillator remains in oversold zone for 1 day
Be on the lookout for a price bounce soon.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where MNOV's RSI Oscillator exited the oversold zone, 20 of 32 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 62%.
The Momentum Indicator moved above the 0 level on November 12, 2026. You may want to consider a long position or call options on MNOV as a result. In 63 of 99 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 64%.
The Moving Average Convergence Divergence (MACD) for MNOV just turned positive on October 28, 2026. Looking at past instances where MNOV's MACD turned positive, the stock continued to rise in 41 of 52 cases over the following month. The odds of a continued upward trend are 79%.
Following a +1.38% 3-day Advance, the price is estimated to grow further. Considering data from situations where MNOV advanced for three days, in 129 of 193 cases, the price rose further within the following month. The odds of a continued upward trend are 67%.
Bearish Trend Analysis
The 10-day moving average for MNOV crossed bearishly below the 50-day moving average on October 09, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 12 of 17 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 71%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where MNOV declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 79%.
The Aroon Indicator for MNOV entered a downward trend on October 29, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 21 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.928) is normal, around the industry mean (3.498). P/E Ratio (-6.952) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (135.135) is also within normal values, averaging (440.869).
The Tickeron PE Growth Rating for this company is 57 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 58 (best 1 - 100 worst), indicating steady price growth. MNOV’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 96 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. MNOV’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
VIR's MACD Histogram just turned positive
The Moving Average Convergence Divergence (MACD) for VIR turned positive on October 27, 2026. Looking at past instances where VIR's MACD turned positive, the stock continued to rise in 34 of 41 cases over the following month. The odds of a continued upward trend are 83%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 27, 2026. You may want to consider a long position or call options on VIR as a result. In 66 of 90 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 73%.
VIR moved above its 50-day moving average on October 26, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for VIR crossed bullishly above the 50-day moving average on October 30, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 13 of 17 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 76%.
Following a +23.82% 3-day Advance, the price is estimated to grow further. Considering data from situations where VIR advanced for three days, in 205 of 268 cases, the price rose further within the following month. The odds of a continued upward trend are 76%.
The Aroon Indicator entered an Uptrend today. In 129 of 159 cases where VIR Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 81%.
Bearish Trend Analysis
The 10-day RSI Indicator for VIR moved out of overbought territory on November 10, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 28 similar instances where the indicator moved out of overbought territory. In 27 of the 28 cases, the stock moved lower in the following days. This puts the odds of a move lower at 90%.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 43 of 53 cases where VIR's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 81%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where VIR declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 81%.
VIR broke above its upper Bollinger Band on November 09, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 19 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.103) is normal, around the industry mean (3.498). P/E Ratio (-6.898) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (5.168) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 35 (best 1 - 100 worst), indicating steady price growth. VIR’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 81 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 96 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. VIR’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
MNOV | VIR | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 9 | 28 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 21 Undervalued | 19 Undervalued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 96 | 96 | |
PRICE GROWTH RATING 1..100 | 58 | 35 | |
P/E GROWTH RATING 1..100 | 57 | 81 | |
SEASONALITY SCORE 1..100 | 50 | n/a |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
VIR's Valuation (19) in the null industry is in the same range as MNOV (21) in the Biotechnology industry. This means that VIR’s stock grew similarly to MNOV’s over the last 12 months.
VIR's Profit vs Risk Rating (100) in the null industry is in the same range as MNOV (100) in the Biotechnology industry. This means that VIR’s stock grew similarly to MNOV’s over the last 12 months.
VIR's SMR Rating (96) in the null industry is in the same range as MNOV (96) in the Biotechnology industry. This means that VIR’s stock grew similarly to MNOV’s over the last 12 months.
VIR's Price Growth Rating (35) in the null industry is in the same range as MNOV (58) in the Biotechnology industry. This means that VIR’s stock grew similarly to MNOV’s over the last 12 months.
MNOV's P/E Growth Rating (57) in the Biotechnology industry is in the same range as VIR (81) in the null industry. This means that MNOV’s stock grew similarly to VIR’s over the last 12 months.
| MNOV | VIR | |
|---|---|---|
| RSI ODDS (%) | 1 day ago 63% | 1 day ago 90% |
| Stochastic ODDS (%) | 1 day ago 88% | 1 day ago 81% |
| Momentum ODDS (%) | 1 day ago 64% | 1 day ago 73% |
| MACD ODDS (%) | 1 day ago 79% | 1 day ago 83% |
| TrendWeek ODDS (%) | 1 day ago 77% | 1 day ago 77% |
| TrendMonth ODDS (%) | 1 day ago 73% | 1 day ago 80% |
| Advances ODDS (%) | 5 days ago 67% | 5 days ago 76% |
| Declines ODDS (%) | 25 days ago 79% | 1 day ago 81% |
| BollingerBands ODDS (%) | N/A | 1 day ago 88% |
| Aroon ODDS (%) | 1 day ago 83% | 1 day ago 81% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
MNOV’s FA Score shows that 1 FA rating(s) are green while VIR’s FA Score has 1 green FA rating(s).
- MNOV’s FA Score: 1 green, 4 red.
- VIR’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
MNOV’s TA Score shows that 5 TA indicator(s) are bullish while VIR’s TA Score has 6 bullish TA indicator(s).
- MNOV’s TA Score: 5 bullish, 3 bearish.
- VIR’s TA Score: 6 bullish, 4 bearish.
Price Growth
MNOV (@Biotechnology) experienced а -3.45% price change this week, while VIR (@Biotechnology) price change was +9.98% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was +2.04%. For the same industry, the average monthly price growth was -6.16%, and the average quarterly price growth was -16.99%.
Reported Earning Dates
MNOV is expected to report earnings on Feb 19, 2027.
VIR is expected to report earnings on Feb 25, 2027.
Industries' Descriptions
@Biotechnology (+2.04% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement
MNOV and
Correlation & Price change
A.I.dvisor indicates that over the last year, MNOV has been loosely correlated with FATE. These tickers have moved in lockstep 36% of the time. This A.I.-generated data suggests there is some statistical probability that if MNOV jumps, then FATE could also see price increases.
| Ticker / NAME | Correlation To MNOV | 1D Price Change % | ||
|---|---|---|---|---|
| MNOV | 100% | -0.71% | ||
| FATE - MNOV | 36% Loosely correlated | -16.51% | ||
| NCEL - MNOV | 36% Loosely correlated | -3.93% | ||
| VIR - MNOV | 29% Poorly correlated | -7.69% | ||
| IMA - MNOV | 28% Poorly correlated | -9.92% | ||
| TIL - MNOV | 28% Poorly correlated | -1.11% | ||
More | ||||
VIR and
Correlation & Price change
A.I.dvisor indicates that over the last year, VIR has been loosely correlated with BEAM. These tickers have moved in lockstep 55% of the time. This A.I.-generated data suggests there is some statistical probability that if VIR jumps, then BEAM could also see price increases.
| Ticker / NAME | Correlation To VIR | 1D Price Change % | ||
|---|---|---|---|---|
| VIR | 100% | -7.69% | ||
| BEAM - VIR | 55% Loosely correlated | -6.90% | ||
| EDIT - VIR | 54% Loosely correlated | -10.08% | ||
| SLDB - VIR | 53% Loosely correlated | -7.89% | ||
| BNTC - VIR | 53% Loosely correlated | -4.01% | ||
| DNLI - VIR | 52% Loosely correlated | -4.26% | ||
More | ||||
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| IJUL | 36.12 | -0.11 | -0.29% |
| Innovator International Developed Power Buffer ETF - July (IJUL) | |||
| TVC | 23.77 | -0.09 | -0.38% |
| Tennessee Valley Authority Power Bonds 1998 Series D due June 1 2028 | |||
| XYLG | 29.29 | -0.15 | -0.50% |
| Global X S&P 500 Covered Call & Growth ETF (XYLG) | |||
| VBCI | 71.82 | -0.61 | -0.84% |
| Vanguard Target Maturity 2035 Corporate Bond ETF (VBCI) | |||
| IGOV | 39.69 | -0.41 | -1.02% |
| iShares International Treasury Bond ETF (IGOV) | |||